HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Doxylamine

HCID 3162
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
469-21-6
Standard SMILES
CN(C)CCOC(C)(c1ccccc1)c1ccccn1
InChIKey
HCFDWZZGGLSKEP-UHFFFAOYSA-N
Molecular formula
C17H22N2O
Average molar mass
270.37 g/mol
Monoisotopic mass
270.17321333

Overview

Doxylamine is a clear colorless liquid. (NTP, 1992)

Names & identifiers

Preferred name
Doxylamine
IUPAC
N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
English name
Doxylamine
Molecular formula
C17H22N2O
Molecular weight
270.37

Names & synonyms

doxylamine469-21-6DossilaminaDoxylaminumDoxilminiodoxilamina2-Dimethylaminoethoxyphenylmethyl-2-picolineN,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanaminePhenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine95QB77JKPLdimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine
Show more names
oxylamineDosilaminNCI C60684(±)-DoxylamineDOXYLAMINE USP/EP/BPDoxylamine Hydrogen inatealpha-Dimethylaminoethoxyphenylmethyl-2-picoline2-[a-(2-dimethylaminoethoxy)-a-methylbenzyl]pyridine
Ethanamine, N,N-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)-DTXSID1022970CHEBI:51380Pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)-Ethanamine, N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]-dimethyl((2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethyl))amine(+-)-DoxylamineRefChem:55070

Database identifiers

Properties

Computed structural propertiesFilling in

XLogP
2.5
Topological polar surface area
25.4 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
6
Heavy atoms
20
Formal charge
0
Complexity
276

Experimental & physicochemical properties

DrugsPharmaceuticals
LogP2.151
Color/FormLIQ
Solubility · 2 items

1 G DISSOLVES IN 1 ML WATER; 1 G DISSOLVES IN 2 ML ALCOHOL; SLIGHTLY SOL IN BENZENE & ETHER; 1 G DISSOLVES IN 2 ML CHLOROFORM /SUCCINATE/

Soluble in acids.

Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Antihistamines; Antiemetics; Gastrointestinal Agents

Pharmaceuticals

Boiling Point · 2 items

279 to 286 °F at 0.5 mmHg (NTP, 1992)

137-141 °C @ 0.5 MM HG

Melting Point · 2 items

< 25 °C

CRYSTALS; MP: 100-104 °C; 1% AQ SOLN HAS PH BETWEEN 4.9 & 5.1 /SUCCINATE/

Vapor PressureSlightly volatile
Refractive Index

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory.

Hazard information

Regulatory Information · 2 items

REACH registered substance: Doxylamine (EC: 207-414-2)

Doxylamine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Ethanamine, N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]-: Environment tier I assessment
Health HazardsSYMPTOMS: Symptoms of exposure to this compound include, drowsiness, vertigo, nervousness, epigastric pain, headache, palpitation, diarrhea, disorientation and irritability.
FDA Requirements · 1 item

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Reactive GroupAmines, Phosphines, and Pyridines
Reactivity Profile · 1 item

DOXYLAMINE is an amine. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides

Chemistry & industry

Pharmacology

ATC Code · 2 items

R - Respiratory system

QR - Respiratory system

Pharmacodynamics · 1 item

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic.

Mechanism of ActionLike other antihistamines, doxylamine acts by competitively inhibiting histamine at H1&nbsp;receptors. It also has substantial sedative and anticholinergic effects.
Biological Half-Life · 2 items

10 hours

The drug has an elimination half-life of about 10 hours in healthy adults.

Metabolism/Metabolites · 4 items

Hepatic.

The conjugated doxylamine metabolites that were isolated, quantitiated, and identified are doxylamine O-glucuronide, N-desmethyl-doxylamine O-glucuronide, and N,N-didesmethyldoxylamine O-glucuronide.

Analysis of doxylamine N-oxide and pyrilamine N-oxide as synthetic standards and biologically derived metabolites by thermospray mass spectrometry (TSP/MS) provided (M + H) + ions for each metabolite. ... In addition, TSP/MS and TSP/MS/MS analysis of ring-hydroxylated N-desmethyldoxylamine ... is also reported.

Hepatic. Half Life: 10 hours

FDA Pharmacological Classification · 5 items

95QB77JKPL

DOXYLAMINE

Established Pharmacologic Class [EPC] - Antihistamine

Mechanisms of Action [MoA] - Histamine Receptor Antagonists

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CAS
469-21-6、562-10-7、76210-47-4
PubChem CID
3162
DTXSID
DTXSID1022970
ChEMBL
CHEMBL1004
ChEBI
CHEBI:51380
UNII
95QB77JKPL
EC Number
207-414-2
Nikkaji
J5.925K
INDEX OF REFRACTION: CALCULATED 1.525 (ALPHA), 1.563 (BETA), 1.598 (GAMMA)
Physical Description · 2 items

Doxylamine is a clear colorless liquid. (NTP, 1992)

Solid

Collision Cross Section · 3 items

162.0 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID7020552]

163.73 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

161.9 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Other Experimental Properties · 2 items

WHITE OR CREAMY WHITE POWDER; CHARACTERISTIC ODOR /SUCCINATE/

Darkens on exposure to light.

Physicochemical properties

Melting point
25 °C · 25°C
Boiling point
0.5 · bp0.5 137-141°
Density
1.0023 · 1.0023 (rough estimate)
refractive index
1.5486 · 1.5486 (estimate)
storage temp.
-20 °C · -20°C Freezer, Under inert atmosphere
solubility
Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
form
Oil
pka
9.2 · pKa 9.20(H2O t = 25 c = 0.002–0.01) (Uncertain);4.4 (Uncertain);9.2 (Uncertain)
color
Colourless
Stability
Temperature Sensitive
InChI
InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
InChIKey
HCFDWZZGGLSKEP-UHFFFAOYSA-N
SMILES
C(N(C)C)COC(C1=CC=CC=C1)(C1=NC=CC=C1)C
FDA UNII
95 QB77JKPL · 95QB77JKPL
ATC code
6 AA09,R06AA59 · R06AA09,R06AA59
EPA Substance Registry System
Doxylamine (469-21-6)
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501
Hazardous Substances Data
469 · 469-21-6(Hazardous Substances Data)
Toxicity
An antihistamine that formerly was used in pregnant women for antihistaminic and sedative properties. Although it has excellent sedative properties, it has been implicated in teratogenesis and in causing neurobehavioral toxicity and is therefore no longer used
REACH Registrations
Active
Air and Water ReactionsNo rapid reaction with air. No rapid reaction with water.
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Safety & protection

Fire Fighting · 1 item

This compound is not very flammable but any fire involving this compound may produce dangerous vapors. You should evacuate the area. All firefighters should wear full-body protective clothing and use self-contained breathing apparatuses. You should extinguish any fires involving this chemical with a dry chemical, carbon dioxide, foam, or halon extinguisher. (NTP, 1992)

First Aid · 1 item

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Storage ConditionsStore below 40 °C (104 °F), preferably between 15 and 39 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a well-closed container. Protect from light.
Nonfire Spill Response · 1 item

SMALL SPILLS AND LEAKAGE: If you should spill this chemical, use absorbent paper to pick up all liquid spill material. Seal the absorbent paper, as well as any of your clothing which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Wash any surfaces you may have contaminated with a strong soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Disposal Methods · 1 item

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Personal Protective Equipment (PPE)MINIMUM PROTECTIVE CLOTHING: When working with this chemical, you should wear impervious coveralls, shoe covers and gloves.

Toxicology

Interactions · 5 items

Concurrent use may potentiate the CNS depressant effects of either these medications /alcohol or other CNS depression-producing medications/ or antihistamines; also, concurrent use of maprotiline or tricyclic antidepressants may potentiate the anticholinergic effects of either antihistamines or these medications. /Antihistamines/

Anticholinergic effects may be potentiated when these medications /anticholinergics or other medications with anticholinergic activity/ are used concurrently with antihistamines; patients should be advised to report occurrence of gastrointestinal problems promptly since paralytic ileus may occur with concurrent therapy. /Antihistamines/

Concurrent use of monoamine oxidase (MAO) inhibitors with antihistamines may prolong the intensify the anticholinergic and CNS depressant effects of antihistamines; concurrent use is not recommended. /Antihistamines/

Concurrent use /of ototoxic medications/ with antihistamines may mask the symptoms of ototoxicity such as tinnitus, dizziness, or vertigo. /Antihistamines/

For more Interactions (Complete) data for DOXYLAMINE (7 total), please visit the HSDB record page.

HepatotoxicityDespite widespread use over many decades, doxylamine has not been linked to liver test abnormalities or to clinically apparent liver injury. The reason for its safety may relate its short half-life and limited duration of use.
Adverse Effects · 1 item

Because doxylamine is available over the counter, the risk of overdose is a concern. Adverse effects due to hypersensitivity to the drug include hypotension, urticaria, and decreased oxygen saturation. Common adverse effects include impaired vigilance, atropine-like effects, impaired coordination, and drowsiness during the day—all of which could pose problems for high-risk fall patients and those operating heavy machinery or who drive a vehicle.

Exposure RoutesReadily absorbed via the gastrointestinal tract.
Toxicity Summary · 2 items

Toxicity associated with antihistamine use is due to overdose following oral ingestion, either unintentional or intentional suicide attempt—most commonly in young and elderly populations. Toxicity from intravenous, intramuscular, or topical routes of administration rarely occurs in the household setting. Toxicity presents as antimuscarinic and hallucinogenic effects. The mnemonic 'dry as a bone, hot as a hare, red as a beet, blind as a bat, full as a flask, and mad as a hatter' has been used to remember the presentation of acute anticholinergic toxicity. This mnemonic represents the findings of anhidrosis, hyperthermia, reddening of the skin, mydriasis, hallucinations, urinary retention, and delirium, respectively.

Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1&nbsp;receptors. It also has substantial sedative and anticholinergic effects.

Signs and SymptomsSigns of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin color, fits, swelling of face, lips, tongue, or throat.
Human Toxicity Excerpts · 5 items

NO EVIDENCE OF TERATOGENIC EFFECTS FOUND IN INFANTS OF 2298 WOMEN WHO TOOK BENDECTIN DURING PREGNANCY.

ASSOC WAS FOUND FOR AMNIOTIC BANDS CASES--A SUBGROUP OF LIMB REDUCTIONS. ASSOC ALSO FOUND WHEN DATA STRATIFIED TO REFLECT 1976 CHANGE IN FORMULATION. THESE STATISTICAL ASSOC DO NOT ESTABLISH CAUSAL RELATIONSHIP BETWEEN BENDECTIN & BIRTH DEFECTS. /BENDECTIN/

IN LARGE, PROSPECTIVE, OBSERVATIONAL STUDY OF PREGNANCY & CHILD DEVELOPMENT, THE ANTINAUSEANT DRUGS PRESCRIBED TO GRAVIDAS FOR NAUSEA & VOMITING IN 1ST 84 DAYS OF PREGNANCY WERE EVALUATED. THERE WAS NO INDICATION THAT BENDECTIN WAS ASSOC WITH TERATOGENIC EFFECTS. /BENDECTIN/

There is considerable controversy regarding the teratogenic potential, if any, of doxylamine; however, after evaluating extensive data and information concerning the possible teratogenicity of the drug, the US Food and Drug Administration (FDA) concluded that it is unlikely that doxylamine is teratogenic. FDA recognizes, however, that despite the large number of pregnancies evaluated to date the possibility that doxylamine may be weakly teratogenic cannot be excluded. Doxylamine was commercially available in the US for the treatment of nausea and vomiting associated with pregnancy in combination with dicyclomine and pyridoxine until 1976, and then in combination with only pyridoxine until 1983 when the manufacturer voluntarily discontinued manufacturing and distributing the combination. Most epidemiologic studies (case-control and cohort) in which fixed combinations of doxylamine and pyridoxine with or without dicyclomine were used during pregnancy indicate that an association between use of these combinations and adverse fetal effects does not appear to exist, but the possibility that the drug is weakly teratogenic cannot be excluded. In a few studies, a weak association between use of the fixed combinations during pregnancy and specific fetal abnormalities (e.g., pyloric stenosis, cardiac defects, oral clefts) was reported, but a causal relationship with the drugs was not established and these findings have not been confirmed by many other studies. Women considering self-medication with doxylamine during pregnancy should consult a health professional for advice regarding the relative risks and benefits of such therapy.

For more Human Toxicity Excerpts (Complete) data for DOXYLAMINE (12 total), please visit the HSDB record page.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

doxylamine

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 5 items

THERAPEUTIC DOSES MAY PRODUCE CNS DEPRESSION & INCOORDINATION, WHILE OVERDOSAGE IS MORE APT TO PRODUCE EXCITEMENT, ATAXIA, & CONVULSIONS. /SUCCINATE/

Most reproduction studies in various animal species using doxylamine and pyridoxine alone or in fixed combination have not revealed evidence of harm to the fetus. Studies in rats and mice using doxylamine succinate dosages up to 125 times the maximum human dosage did not reveal evidence of observable congenital abnormalities, but wavy ribs and diaphragmatic hernias occurred in rats at dosages 125-375 times the maximum human dosage; an overall increase in fetal wastage, varying from zero to threefold, occurred in most rodents receiving dosages 125 or more times greater than the maximum human dosage. In a small study in monkeys receiving a fixed combination of doxylamine succinate and pyridoxine hydrochloride throughout fetal organogenesis at dosages 10-20 times the maximum human dosage, intraventricular septal defects were present in 4 of 7 fetuses delivered on day 100 of gestation (full-term gestation is about 160 days), while 2 fetuses aborted on the 46th and 56th day of gestation appeared to be developing normally and 3 other fetuses allowed to develop to term were normal. The importance of septal defects in these monkeys is not known, since an opening in the septum is usually present early during fetal development in monkeys. In other studies in monkeys receiving the fixed combination for shorter periods of time, there was no evidence of fetal toxicity.

The objective of this study was to provide a qualitative description of the histological and ultrastructural alterations induced by three chondrogenesis inhibitors: retinoic acid and 6-aminonicotinamide, two teratogens, and doxylamine succinate, a nonteratogen cmpd. In addition, in order to have a basis for the interpretation of the morphological alterations induced by the test cmpd, the histological and ultrastructural changes which occur during the time course of chondrogenesis in control cultures were described and compared with those in rat embryo limb buds. ... Doxylamine succinate at 50 ug/ml affected both differentiation and proliferation; pigment deposits were observed in chondrocytes, suggesting phospholipid metabolism disorders. /Doxylamine succinate/

We assessed the effectiveness of five in vitro assays in predicting in vivo tumor growth stimulation by the H1-antihistamines loratadine, astemizole, cetirizine, bydroxyzine, and doxylamine. ... Potency of each agent was ranked 1-5 in each of the following in vitro assays: 1) inhibition of (3H)histamine binding to microsomal HIC, 2) inhibition of histamine binding to microsomal P450, 3) inhibition of the P450-catalyzed demethylation of aminopyrine, 4) inhibition of lymphocyte mitogenesis, and 5) stimulation of tumor colony formation. An overall rank score was assigned to each drug and correlated with tumor growth stimulation in vivo. Two laboratories conducted in vivo studies in a blinded fashion. Female C57Bl and C3H mice were given a sc injection on day 1 of syngeneic B16F10 melanoma cells (5), respectively. Mice were randomly assigned to treatment groups, then received a single, daily ip injection of an estimated human-equivalent dose (or range of doses) of antihistamine or vehicle control for 18-21 days before being killed. Tumors were surgically removed and wet weights compared statistically among groups. ... The cumulative potency of each drug in affecting tumor growth or growth mechanisms in the five in vitro assays ranked as follows: Loratidine and astemizole ranked highest and were equally potent, followed in decreasing order by hydroxyzine, doxylamine, and cetirizine. A significant correlation (r = 0.97; p < 0.02) was observed between the rank order of potency of the antihistamines in all five in vitro assays and the rank order to enhance tumor growth in vivo:Loratidine and astemizole significantly (p < 0.001) promoted the growth of both melanoma and fibrosarcoma, hydroxyzine significantly (p < 0.001) promoted the growth of melanoma, while doxylamine and cetirizine did not promote the growth of either tumor.

Evidence for Carcinogenicity · 1 item

Evaluation: There is inadequate evidence in humans for the carcinogenicity of doxylamine succinate. There is limited evidence in experimental animals for the carcinogenicity of doxylamine succinate. Overall evaluation: Doxylamine succinate is not classifiable as to its carcinogenicity in humans (Group 3). /Doxylamine succinate/

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Regulatory information

FDA Requirements · 1 item

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Safety data

Toxicity
An antihistamine that formerly was used in pregnant women for antihistaminic and sedative properties. Although it has excellent sedative properties, it has been implicated in teratogenesis and in causing neurobehavioral toxicity and is therefore no longer used
Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H319-H335
REACH Registrations
Active
Precautionary statements
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501
Hazardous Substances Data
469-21-6(Hazardous Substances Data)

Doxylamine is an Antihistamine. The mechanism of action of doxylamine is as a Histamine Receptor Antagonist.

MeSH Pharmacological Classification · 2 items

Drugs used to prevent NAUSEA or VOMITING.

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.

Absorption, Distribution and Excretion · 5 items

Readily absorbed via the gastrointestinal tract.

H1 antagonists are eliminated more rapidly by children than by adults and more slowly in those with severe liver disease. /H1 Receptor Antagonists/

The H1 antagonists are well absorbed from the gastrointestinal tract. Following oral administration, peak plasma concentrations are achieved in 2 to 3 hours ... . /H1 Receptor Antagonists/

Elimination and metabolic profiles of the glucuronide products of doxylamine and its N-demethylated metabolites were determined after the oral admin of (14)C-doxylamine succinate (13.3 and 133 mg/kg doses) to male and female Fischer 344 rats. The cumulative urinary and fecal eliminations of these conjugated doxylamine metaboites at the 13.3 mg/kg dose were 44.4 + or - 4.2% and 47.3 + or - 8.1% of the total recoverd dose for male and female rats, respectively. The cumulative urinary and fecal eliminations of conjugated doxylamine metabolites at the 133 mg/kg dose were 55.2 + or - 2.6% and 47.9 + or - 2.5% of the total recovered dose for male and female rats, respectively. The conjugated doxylamine metabolites that were isolated, quantitiated, and identified are doxylamine O-glucuronide, N-desmethyl-doxylamine O-glucuronide, and N,N-didesmethyldoxylamine O-glucuronide.

The elimination of doxylamine and metabolites was determined after iv admin of (14)C-doxylamine succinate at 0.7 and 13.3 mg/kg to the adult female rhesus monkey. Although the total recovery of radioactivity was the same for the low- and high-dose studies (90.2%), the rate of plasma elimination of doxylamine and its demethylated metabolite (desmethyldoxylamine) was slower for the high dose group. The 24 hr urinary excretion of doxylamine metabolites, desmethyl- and didesmethyldoxylamine, was significantly incr and the polar doxylamine metabolites were significantly decr as the iv doxylamine succinate dose was incr. The plasma elimination of GC-detected doxylamine was determined after po admin of Bendectin (doxylamine succinate and pyridoxine hydrochloride) /also contains dicyclomine hydrochloride/ at 7, 13.3, and 27 mg/kg to adult female rhesus monkeys. As the dose incr, the clearance of doxylamine decr. A statistically evaluated fit of the po data to a single-compartment, parallel first-order elimination model and a single-compartment, parallel first- and second-order (Michaelis-Menten) elimination model indicated that the more complex model containing the second-order process was most consistent with the observed elimination data. /Doxylamine succinate/

Cellular LocationsMembrane
Metabolite PathwaysDoxylamine H1-Antihistamine Action

Uses & manufacturing

Uses · 3 items

MEDICATION

Use (kg; approx.) in Germany (2009): >1000

Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.

U.S. Exports · 2 items

(1977) No Data

(1979) No Data

U.S. Imports · 2 items

(1977) 5X10+4 G-PRINCPL CUSTMS DISTS-SUCCINATE

(1979) 4X10+5 G-PRINCPL CUSTMS DISTS-SUCCINATE

U.S. Production · 2 items

(1977) PROBABLY MORE THAN 9.1X10+5 G-SUCCINATE

(1979) PROBABLY MORE THAN 9.1X10+5 G-SUCCINATE

Methods of Manufacturing · 3 items

PREPD FROM PHENYL-2-PYRIDYLMETHYLCARBINOL & BETA-N,N-DIMETHYLAMINOETHYL CHLORIDE IN PRESENCE OF SODAMIDE IN XYLENE... SPERBER ET AL., J AM CHEM SOC 71,887 (1949)

2-Acetylpyridine + phenylmagnesium bromide + 2-dimethylaminoethyl chloride hydrochloride (Grignard reaction/ether formation)

Pyridine + acetophenone + 2-diethylaminoethyl chloride hydrochloride (Grignard reagent formation/Grignard reaction/ether formation)

Formulations/Preparations · 5 items

SYRUP NF: 6.25 MG/5 ML; TABLETS NF: 12.5 & 25 MG. /SUCCINATE/

PDR(34TH ED) 1205 (1980). EACH SPECIALLY COATED BENDECTIN TABLET CONTAINS: DECAPRYN (DOXYLAMINE SUCCINATE)--ANTIHISTAMINE 10 MG; PYRIDOXINE HYDROCHLORIDE 10 MG.

Available commercially as the hydrogen succinate.

Mereprine, Alsadorm, Decapryn succinate, Gittalun, Hoggar N, Sedaplus, Unisom /Succinate/

A combination with pyridoxine hydrochloride /which/ has been marketed as Bendectin for nausea of pregnancy.

Use ClassificationPharmaceuticals
General Manufacturing InformationA COMBINATION WITH METHYLETHYLAMINOPHENOLPROPANOL HCL (NETHAMINE) & THEOPHYLLINE AMINOISOBUTANOL IS MARKETED AS NETHAPRIN.
Applications · 3 items

UsesAntihistaminic.

Uses(±)-Doxylamine is an intermediate in the synthesis of Doxylamine N, N’-Dioxide (D562025), which is an impurity of Doxylamine (succinate salt, D562000), which is an H1 Histamine receptor antagonist.

General DescriptionClear colorless liquid.

Upstream & downstream products

Downstream products

Butanedioic acid, compd. with (+)-N,N-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine (1:1) (9CI)

Additional notes

DefinitionChEBI: Doxylamine is a member of pyridines and a tertiary amine. It has a role as a histamine antagonist, a cholinergic antagonist, a sedative, an antiemetic, a H1-receptor antagonist, an anti-allergic agent and an antitussive.

For more Non-Human Toxicity Excerpts (Complete) data for DOXYLAMINE (9 total), please visit the HSDB record page.